Mats Ahlberg, Hans Garmo, Pär Stattin, Rolf Gedeborg, Christer Edlund, Lars Holmberg, Anna Bill-Axelson
{"title":"2008-2020 年前列腺癌从积极监测转为根治性治疗的诱因--病例对照研究。","authors":"Mats Ahlberg, Hans Garmo, Pär Stattin, Rolf Gedeborg, Christer Edlund, Lars Holmberg, Anna Bill-Axelson","doi":"10.2340/sju.v59.34803","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To examine associations between objective signs of progression (triggers) and transition from active surveillance (AS) to radical treatment for prostate cancer (PC).</p><p><strong>Patients and methods: </strong>This case-control study included men with low- or favourable intermediate-risk PC in the region of Halland, with data from The National Prostate Cancer Register (NPCR), Sweden, starting AS between 2008 and 2020. Cases were men who transitioned to radical treatment. For each case, 10 controls who remained in AS were selected without further matching. Triggers for transition to treatment were histopathological progression, magnetic resonance imaging (MRI) progression and increases in prostate-specific antigen (PSA) levels. We compared the probabilities for triggers between cases and controls, in 2008-2014 and 2015-2020, using logistic regression.</p><p><strong>Results: </strong>Amongst 846 men, we identified 98 cases in 2008-2014 and 172 cases in 2015-2020. Histopathological progression was associated with transition, most strongly in the later period (2008-2014: odds ratios [OR] 6.88, 95% confidence interval [CI] 3.69-12.80; and 2015-2020: OR 75.29, 95% CI 39.60-143.17). MRI progression was associated with transition in 2015-2020 (OR 6.38, 95% CI 2.70-15.06), whereas an increase in PSA was weakly associated with transition in the early period. The absence of triggers was associated with no transition (2008-2014: OR 0.24, 95% CI 0.15-0.40, and 2015-2020: OR 0.09, 95% CI 0.06-0.14). The probability of no trigger was 27% in cases 2015-2020.</p><p><strong>Conclusion: </strong>The increase in association between histopathological trigger and transition to treatment indicates increased quality of AS. Still, amongst men treated from 2015 to 2020, 27% transitioned without any trigger.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"59 ","pages":"63-69"},"PeriodicalIF":1.4000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study.\",\"authors\":\"Mats Ahlberg, Hans Garmo, Pär Stattin, Rolf Gedeborg, Christer Edlund, Lars Holmberg, Anna Bill-Axelson\",\"doi\":\"10.2340/sju.v59.34803\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To examine associations between objective signs of progression (triggers) and transition from active surveillance (AS) to radical treatment for prostate cancer (PC).</p><p><strong>Patients and methods: </strong>This case-control study included men with low- or favourable intermediate-risk PC in the region of Halland, with data from The National Prostate Cancer Register (NPCR), Sweden, starting AS between 2008 and 2020. Cases were men who transitioned to radical treatment. For each case, 10 controls who remained in AS were selected without further matching. Triggers for transition to treatment were histopathological progression, magnetic resonance imaging (MRI) progression and increases in prostate-specific antigen (PSA) levels. We compared the probabilities for triggers between cases and controls, in 2008-2014 and 2015-2020, using logistic regression.</p><p><strong>Results: </strong>Amongst 846 men, we identified 98 cases in 2008-2014 and 172 cases in 2015-2020. Histopathological progression was associated with transition, most strongly in the later period (2008-2014: odds ratios [OR] 6.88, 95% confidence interval [CI] 3.69-12.80; and 2015-2020: OR 75.29, 95% CI 39.60-143.17). MRI progression was associated with transition in 2015-2020 (OR 6.38, 95% CI 2.70-15.06), whereas an increase in PSA was weakly associated with transition in the early period. The absence of triggers was associated with no transition (2008-2014: OR 0.24, 95% CI 0.15-0.40, and 2015-2020: OR 0.09, 95% CI 0.06-0.14). The probability of no trigger was 27% in cases 2015-2020.</p><p><strong>Conclusion: </strong>The increase in association between histopathological trigger and transition to treatment indicates increased quality of AS. Still, amongst men treated from 2015 to 2020, 27% transitioned without any trigger.</p>\",\"PeriodicalId\":21542,\"journal\":{\"name\":\"Scandinavian Journal of Urology\",\"volume\":\"59 \",\"pages\":\"63-69\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2340/sju.v59.34803\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/sju.v59.34803","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的研究客观进展迹象(触发因素)与前列腺癌(PC)从积极监测(AS)转为根治性治疗之间的关系:这项病例对照研究纳入了哈兰德地区患有低危或良好中危前列腺癌的男性患者,其数据来自瑞典国家前列腺癌登记处(NPCR)。病例为接受根治性治疗的男性。每个病例均选取 10 名仍在接受 AS 治疗的对照者,无需进一步匹配。转为治疗的触发因素包括组织病理学进展、磁共振成像(MRI)进展和前列腺特异性抗原(PSA)水平的升高。我们使用逻辑回归法比较了 2008-2014 年和 2015-2020 年病例和对照组的触发概率:在 846 名男性中,我们发现 2008-2014 年有 98 例,2015-2020 年有 172 例。组织病理学进展与转归相关,在后期最为明显(2008-2014 年:几率比[OR] 6.88,95% 置信区间[CI] 3.69-12.80;2015-2020 年:几率比[OR] 75.29,95% 置信区间[CI] 3.69-12.80):75.29,95% 置信区间为 39.60-143.17)。MRI 进展与 2015-2020 年的转归相关(OR 6.38,95% CI 2.70-15.06),而 PSA 增高与早期转归关系不大。无触发因素与无转归相关(2008-2014 年:或 0.24,95% CI 0.15-0.40;2015-2020:或 0.09,95% CI 0.15-0.40:或 0.09,95% CI 0.06-0.14)。在2015-2020年的病例中,无触发概率为27%:组织病理学诱发因素与转为治疗之间的关联性增加,表明强直性脊柱炎的质量有所提高。尽管如此,在2015年至2020年接受治疗的男性中,仍有27%的人在没有任何触发因素的情况下转入治疗。
Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study.
Objective: To examine associations between objective signs of progression (triggers) and transition from active surveillance (AS) to radical treatment for prostate cancer (PC).
Patients and methods: This case-control study included men with low- or favourable intermediate-risk PC in the region of Halland, with data from The National Prostate Cancer Register (NPCR), Sweden, starting AS between 2008 and 2020. Cases were men who transitioned to radical treatment. For each case, 10 controls who remained in AS were selected without further matching. Triggers for transition to treatment were histopathological progression, magnetic resonance imaging (MRI) progression and increases in prostate-specific antigen (PSA) levels. We compared the probabilities for triggers between cases and controls, in 2008-2014 and 2015-2020, using logistic regression.
Results: Amongst 846 men, we identified 98 cases in 2008-2014 and 172 cases in 2015-2020. Histopathological progression was associated with transition, most strongly in the later period (2008-2014: odds ratios [OR] 6.88, 95% confidence interval [CI] 3.69-12.80; and 2015-2020: OR 75.29, 95% CI 39.60-143.17). MRI progression was associated with transition in 2015-2020 (OR 6.38, 95% CI 2.70-15.06), whereas an increase in PSA was weakly associated with transition in the early period. The absence of triggers was associated with no transition (2008-2014: OR 0.24, 95% CI 0.15-0.40, and 2015-2020: OR 0.09, 95% CI 0.06-0.14). The probability of no trigger was 27% in cases 2015-2020.
Conclusion: The increase in association between histopathological trigger and transition to treatment indicates increased quality of AS. Still, amongst men treated from 2015 to 2020, 27% transitioned without any trigger.
期刊介绍:
Scandinavian Journal of Urology is a journal for the clinical urologist and publishes papers within all fields in clinical urology. Experimental papers related to clinical questions are also invited.Important reports with great news value are published promptly.